Fed Bioequivalence Study of 2 Metformin 1000 mg Prolonged Release Tablets in 28 Healthy Male and Female Volunteers

Inclusion Criteria: * Healthy males and non-pregnant and no breast-feeding females (must have a negative pregnancy test result prior to dosing), Caucasian race. * Non-smoker or past-smoker (who has stopped smoking at least 6 months before the first dosing). * Body Mass Index (BMI) 18.5 to 30.0 kg/m2, inclusive and body weight between 50 kg and 100 kg(on the day of screening). * Subject was available for the whole study and had provided his/her written informed consent. * Subjects in good health, as determined by screening medical history, physical examination, vital signs assessments (pulse rate, systolic and diastolic blood pressure, and body temperature) and 12-lead ECG (electrocardiogram). Minor deviations outside the reference ranges were acceptable, if deemed not clinically significant by the Investigator. * Subjects in good health, as determined by screening clinical laboratory evaluations. Minor deviations outside the reference ranges were acceptable, if deemed not clinically significant by the Investigator. * Acceptance of use of contraceptive measures during the whole study by both female and male subjects. Exclusion Criteria: * Known cardiovascular disease, history of hypotension. * Factors in the subject's history that might predispose to ketoacidosis (including pancreatic insulin deficiency, history of pancreatitis, caloric restriction disorders, restricted food intake, alcohol abuse) * Gastrointestinal, renal or hepatic diseases and/or pathological findings present or in history, which might interfere with the drug pharmacokinetics. * Previous liver disease with elevations in serum transaminases. * Acute or chronic diseases and/or clinical finding which might interfere with the aims of the study or with the drug's safety, tolerability, bioavailability and/or pharmacokinetics of the Investigational Medicinal Product (IMP). * History of kidney disease and with impaired renal function. * History of severe allergy or allergic reactions to the study IMP, its excipients or related drugs. * Clinically significant illness within 28 days before the first dosing, including major surgery. * Any significant clinical abnormality including Hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), and / or (human immunodeficiency virus) HIV. (On screening) * Positive screening urine drugs abuse test or/and alcohol breath test or urine cotinine test, and positive pregnancy test on screening. * Serious mental disease and/or inability to cooperate with clinical team. * Sitting blood pressure after a minimum of 5 minutes of rest is out of the range of 100-140 mmHg for systolic blood pressure (BP) and/or 60-100 mmHg for diastolic BP and/or heart rate out of the range of 50-100 bpm during the screening procedure. * Body ear temperature was out of the range of 35.7-37.6°C at screening. * Orthostatic hypotension during the screening procedure. * Drug, alcohol (of ≥ 40 g per day pure ethanol), solvents or caffeine abuse. * Use of organ-toxic drugs or systemic drugs known to substantially alter liver metabolism within 90 days before the first dosing. * Use of any prescription medication for a period of 28 days before the first dosing. * Any systemic over-the-counter (OTC) drug treatment and/or vitamins and/or herbal treatment/or food supplements within 14 days before the first dosing. * Getting a tattoo, body piercing or any cosmetic treatment involving skin piercing within 90 days before the screening unless evaluated by Investigator as non-significant for inclusion in the study. * Donation or loss of at least 500 mL of blood within 90 days or donation of plasma or platelets within 14 days before the first dosing. * Anaemia, haemoglobin below 120 g/L for women and 130 g/L for men at screening. * Less than 30 days between exit procedure in previous study and the first dosing in this study.